StockData

Mosaic ImmunoEngineering Inc. (CPMV) stock

CPMVOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 3/30
$0.33+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.41MP/E –Yield –

Mosaic ImmunoEngineering operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Mosaic ImmunoEngineering's operating income for the twelve months ending Jun 30, 2026 was -$604.01K. For fiscal 2025 it was -$616.12K.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$616.12K–
FY2024Dec 31, 2024-$879.66K–
FY2023Dec 31, 2023-$1.40M–
FY2022Dec 31, 2022-$2.63M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$156.72K–
Q1 FY2026CQ1 2026Mar 31, 2026-$154.80K–
Q4 FY2025CQ4 2025Dec 31, 2025-$148.13K–
Q3 FY2025CQ3 2025Sep 30, 2025-$144.36K–
Q2 FY2025CQ2 2025Jun 30, 2025-$148.85K–
Q1 FY2025CQ1 2025Mar 31, 2025-$174.77K–
Q4 FY2024CQ4 2024Dec 31, 2024-$150.16K–
Q3 FY2024CQ3 2024Sep 30, 2024-$186.43K–
Q2 FY2024CQ2 2024Jun 30, 2024-$274.30K–
Q1 FY2024CQ1 2024Mar 31, 2024-$268.77K–
Q4 FY2023CQ4 2023Dec 31, 2023-$275.62K–
Q3 FY2023CQ3 2023Sep 30, 2023-$311.87K–
Q2 FY2023CQ2 2023Jun 30, 2023-$352.51K–
Q1 FY2023CQ1 2023Mar 31, 2023-$459.77K–
Q4 FY2022CQ4 2022Dec 31, 2022-$497.55K–
Q3 FY2022CQ3 2022Sep 30, 2022-$517.21K–
Q2 FY2022CQ2 2022Jun 30, 2022-$883.73K–
Q1 FY2022CQ1 2022Mar 31, 2022-$729.04K–

More Mosaic ImmunoEngineering figures

See a number that looks wrong?